Prohost Biotech - Exclusive Biotech Research - A Comprehensive Resource for Biotech News

Why Cassava Sciences Stock Opened Down Today. See Also: The Mirati Therapeutics and MD Anderson Collaboration

February 10, 2021 2

Cassava Sciences Inc Opened Down Today Cassava Sciences, Inc. (SAVA) - a clinical-stage biotech firm focused on …

Cassava Sciences: Significant Program Progress and its Expected Milestones for 2021

February 8, 2021 0

Cassava Sciences 2021 Focus and Momentum Cassava Sciences (SAVA) President & CEO, Remi Barbier, informed that …

Researchers at the Children’s Hospital of Philadelphia are Improving Gene Therapy Vectors

February 5, 2021 0

The Children’s Hospital of Philadelphia: Improving Gene Therapy Vectors Improving gene therapy vectors seems to have …

Roche and Spark Therapeutics: Gene Therapy SPK-8016 Demonstrating Promising Results on Adults with Severe Hemophilia A

February 5, 2021 0

Roche Group and Spark Therapeutics Gene Therapy Showing Promising Results Looking for gene therapy treatments for …

Cassava Sciences Product, Simufilam, Improved the Cognition and Behavior of Alzheimer’s Patients Following Six Months of Treatment

February 2, 2021 2

Cassava Sciences Announced Simufilam Results for Alzheimer's Cassava Sciences (SAVA) announced impressive results of an interim …

Amgen is Still the King of the Biotech Sector

January 30, 2021 0

Amgen KRAS Inhibitor, Sotorasib Amgen (AMGN) has taken on one of the toughest challenges in the last …

Moderna COVID-19 Vaccine Produced Neutralizing Titers Against Key Emerging Variants Tested

January 28, 2021 0

Moderna COVID-19 Vaccination News A vaccination with the Moderna (MRNA) COVID-19 produced neutralizing titers against all …

CASI Partner, BioInvent, Announced the Combination of Rituximab with BI-1206 restored riruximab’s Capability to Treat Indolent Relapsed or Refractory B-cell non-Hodgkin’s Lymphoma

January 28, 2021 0

CASI Pharmaceuticals Partner, BioInvent International, Announced Positive Interim Results for NHL CASI Pharmaceuticals (CASI) partner BioInvent …

Aurinia Pharmaceuticals: FDA Approved LUPKYNIS for Active Lupus Nephritis in Adults

January 27, 2021 0

Aurinia Pharmaceuticals LUPKYNIS Approved for LN in Adults Aurinia Pharmaceuticals (AUPH) has been granted a U.S. …

Merck Has Interesting News and Impressive Results

January 26, 2021 0

Merck Discontinues Development of COVID-19 Vaccine Candidates Merck (MRK) known as MSD outside the United States and …

ViiV Healthcare: The FDA Approved Cabenuva for Adults Who are HIV Virologically-Suppressed

January 25, 2021 0

ViiV Healthcare Announced FDA Approval for Cabenuva for Adults with HIV-1 From London we learned that …

Exelixis: The FDA Approved Cabometyx in Combination with Opdivo as a First Line Treatment of RCC

January 23, 2021 0

Exelixis: FDA Approval for Cabometyx in Combination with Opdivo Exelixis (EXEL) announced that the United States FDA …

Compugen: Why the Great Expectations from this Firm

January 22, 2021 0

The Compugen Story For those who are still asking about the value of Compugen’s (CGEN) discoveries …

Sutro Biopharma Dosed the First Patient in the Dose-Expansion Cohort of the Phase 1 STRO-002 Study

January 21, 2021 0

Sutro Biopharma Therapeutic Discovery and Technology Sutro Biopharma (STRO) uses precise protein engineering and rational design …

News About Reata Pharmaceuticals

January 19, 2021 0

Reata Pharmaceuticals The Positive News Prohost Biotech's interest in Reata Pharmaceuticals (RETA) started when we recognized …

bluebird bio: The Appealing Decision to Separate its Severe Genetic Disease and Oncology Businesses into Independent Publicly-Traded Firms

January 14, 2021 0

bluebird bio Decision to Separate its Businesses bluebird bio (BLUE) will retain focus on its severe genetic …

Exclusive Market Insight

& Scientific analysis

Latest Articlesddd

Why Cassava Sciences Stock Opened Down Today. See Also: The Mirati Therapeutics and MD Anderson Collaboration

Cassava Sciences: Significant Program Progress and its Expected Milestones for 2021

Researchers at the Children’s Hospital of Philadelphia are Improving Gene Therapy Vectors

Roche and Spark Therapeutics: Gene Therapy SPK-8016 Demonstrating Promising Results on Adults with Severe Hemophilia A

Cassava Sciences Product, Simufilam, Improved the Cognition and Behavior of Alzheimer’s Patients Following Six Months of Treatment

Amgen is Still the King of the Biotech Sector

Moderna COVID-19 Vaccine Produced Neutralizing Titers Against Key Emerging Variants Tested

CASI Partner, BioInvent, Announced the Combination of Rituximab with BI-1206 restored riruximab’s Capability to Treat Indolent Relapsed or Refractory B-cell non-Hodgkin’s Lymphoma

Aurinia Pharmaceuticals: FDA Approved LUPKYNIS for Active Lupus Nephritis in Adults

Merck Has Interesting News and Impressive Results

ViiV Healthcare: The FDA Approved Cabenuva for Adults Who are HIV Virologically-Suppressed

Exelixis: The FDA Approved Cabometyx in Combination with Opdivo as a First Line Treatment of RCC

Compugen: Why the Great Expectations from this Firm

Sutro Biopharma Dosed the First Patient in the Dose-Expansion Cohort of the Phase 1 STRO-002 Study

News About Reata Pharmaceuticals

bluebird bio: The Appealing Decision to Separate its Severe Genetic Disease and Oncology Businesses into Independent Publicly-Traded Firms

La Jolla Pharmaceutical Company Announced an Exclusive Licensing Agreement for GIAPREZA and XERAVA in Europe

Underlining Exelixis Bright Future

For Those Still Asking Why the CRiSPR Gene Editing Stocks are Soaring

Rhythm Pharmaceuticals: Successful Results from Phase 3 Trial with Setmelanotide for Obesity Caused by Genetic BBS